We are Fulfilling Unmet Needs in Pulmonary Medicine. Aradigm is an emerging specialty pharmaceutical company developing and commercializing a portfolio of drugs delivered by inhalation for the treatment of severe respiratory disease. Bolstered by its depth of expertise in pulmonary drug delivery and an extensive intellectual property portfolio, the Company is uniquely positioned to fulfill unmet needs in pulmonary medicine. Our corporate strategy includes the following: • Continued development of proprietary respiratory disease therapies • Pursue regulatory pathways that reduce the time, costs and risks associated with product development • Conservation of capital for proprietary product development through the outsourcing of late stage clinical and commercial scale manufacturing • Deployment of a specialized sales and marketing force to meet the unique needs of pulmonologists in the United States • Out-licensing technology and intellectual property assets for applications that lie outside the company's strategic interests and core expertise
Company Growth (employees)
Type
Public
HQ
Hayward, US
Size (employees)
16 (est)
Aradigm is headquartered in Hayward, US

Key People at Aradigm

Igor Gonda

Igor Gonda

President & Chief Executive Officer
Nancy Pecota

Nancy Pecota

Chief Financial Officer

Aradigm Office Locations

Aradigm has an office in Hayward
Hayward, US (HQ)
3929 Point Eden Way

Aradigm Data and Metrics

Aradigm Financial Metrics

Aradigm's revenue was reported to be $23.4 m in FY, 2015 which is a 30% decrease from the previous period.
USD

Revenue (FY, 2015)

23.4 m

Revenue growth (FY, 2014 - FY, 2015), %

(30%)

Net income (FY, 2015)

(17.2 m)

EBIT (FY, 2015)

(17.2 m)

Market capitalization (26-Jun-2017)

19.5 m

Closing share price (26-Jun-2017)

1.4

Cash (31-Dec-2015)

31.5 m
Aradigm's current market capitalization is $19.5 m.
USDFY, 2013FY, 2014FY, 2015

Revenue

9.7 m33.6 m23.4 m

Revenue growth, %

245%(30%)

Operating expense total

29.6 m37.4 m40.6 m

EBIT

(19.9 m)(3.9 m)(17.2 m)

EBIT margin, %

(205%)(11%)(73%)

Interest expense

1.6 m288 k288 k

Interest income

6 k17 k29 k

Net Income

(21.6 m)4.7 m(17.2 m)
USDFY, 2013FY, 2014FY, 2015

Cash

48.1 m48 m31.5 m

Current Assets

49.7 m50.5 m35.2 m

PP&E

400 k502 k299 k

Total Assets

50.4 m54 m35.6 m

Accounts Payable

619 k2.7 m1.8 m

Current Liabilities

7.3 m6.8 m7.5 m

Retained Earnings

(392.9 m)(388.3 m)(405.5 m)

Total Equity

33.7 m39.1 m23.1 m

Financial Leverage

1.5 x1.4 x1.5 x
USDFY, 2013FY, 2014FY, 2015

Net Income

(21.6 m)4.7 m(17.2 m)

Depreciation and Amortization

370 k310 k203 k

Accounts Payable

289 k2.1 m(917 k)

Cash From Operating Activities

264 k107 k(16.7 m)

Capital Expenditures

(43 k)(412 k)(412 k)

Cash From Investing Activities

131 k(412 k)(412 k)

Cash From Financing Activities

40.3 m164 k175 k

Free Cash Flow

307 k519 k(16.3 m)
USDY, 2015

Revenue/Employee

1.4 m

Financial Leverage

1.5 x

Aradigm Operating Metrics

FY, 2014FY, 2015FY, 2016

Patents Pending

352749

Patents Issued

828280

    Aradigm Market Value History

    Aradigm Company Life and Culture

    You may also be interested in